MedPath

RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer

Not Applicable
Recruiting
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Other: Blood sample
Registration Number
NCT04575363
Lead Sponsor
CHU de Reims
Brief Summary

PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and specificity.

Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different cellular functions such as cell adhesion, migration, proliferation and differentiation. The expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic, etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities. Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC. Recent data suggest that a modification of the RPSA concentration could be a prognostic biomarker of PDAC.

Detailed Description

The aim of this study is to explore the potential implication of RPSA as prognostic biomarker of PDAC.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria

Not provided

Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
pancreatic adenocarcinoma patientBlood samplepatient with pancreatic ductal adenocarcinoma
Primary Outcome Measures
NameTimeMethod
RPSA serum concentrationDay 0

The RPSA serum concentration is assessed with commercially available RPSA ELISA assay (MyBioSource - MBS9137288).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Damien JOLLY

🇫🇷

Reims, France

© Copyright 2025. All Rights Reserved by MedPath